

Panion Animal Health AB carries out a rights issue of approximately SEK 7.7 million

Panion today announced that the Board of Panion Animal Health AB ("Panion" or "Company") on 28 November 2018, with the authorization of the Annual General Meeting of 29 May 2018, decided to issue a new issue of 7,687,374 shares with preferential rights for existing shareholder. The subscription price in the rights issue is SEK 1, which, in full subscription, will provide the company with approximately SEK 7.7 million before issuing costs of approximately SEK 0.2 million.

Terms and schedule for the rights issue.

The right to subscribe is primarily the Company's shareholders who receive a subscription right for each share.

For each share in the Company held on the record date, one (1) subscription right is obtained. Three (3) subscription rights entitle to subscription of one (1) new share.

The subscription price amounts to SEK 1 per share. The rights issue includes no more than 7,687,374 shares. Reconciliation date for the right to receive subscription rights is December 5, 2018.

The last day for trading with the Panion share including the right to receive subscription rights is December 3, 2018. The share is traded exclusive of subscription rights as of December 4, 2018.

The subscription period is December 7 - December 21, 2018.

Trading in subscription rights will take place on Spotlight Stock Market during the period 7 December - 19 December 2018. Trade with BTA will take place on Spotlight Stock Market as of December 7, 2018 until Bolagsverket has registered the rights issue. The Board of Directors of the Company is entitled to extend the subscription and payment period.

Terms and conditions for the new issue and more detailed information about the new issue

The Board of Panion decided on November 28, 2018, with the authorization given at the Annual General Meeting on May 29, 2018, about a new issue of 7,687,374 shares with preferential rights for existing shareholders. The Company's existing shareholders will receive subscription rights for subscription of shares in proportion to the number of shares they own on the record date of December 5, 2018.

Each existing share in the Company entitles one (1) subscription right. Three (3) subscription rights entitle the holder to subscribe for one (1) new share at the subscription price of SEK 1 per share. Upon full subscription, the Company will receive approximately SEK 7.7 million before issue costs of approximately SEK 0.2 million.

Unless all shares are subscribed for by virtue of subscription rights, the granting of new shares subscribed for without subscription rights shall primarily be made to such subscribers who also subscribed for new shares on the basis of subscription rights, whether or not the subscriber was a shareholder on the record date or not. In cases where allotment to these cannot be fully realized, allocation shall be pro rata in proportion to the number of subscription rights used for subscription of new shares and, to the extent that this cannot be done by lottery. On the other hand, the assignment of new shares subscribed for without subscription rights to other subscribers without subscription rights and, in the event that their allocation cannot be fully realized, the allocation shall be proportional to the number of new shares each subscribed and, as far as this cannot be done, by lottery.

For additional information, contact:

Anja E. H. Holm, CEO | +45-22 94 66 00
anja.holm@panion-animalhealth.com

Panion Animal Health AB
info@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at Spotlight Stock Market.

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 
twitter.com/panionanihealth 
panion-animalhealth.com/newsletter 
panion-animalhealth.com 

Shares and share capital

The rights issue represents an increase, in full subscription, of the share capital by SEK 358,261.44 from SEK 1,074,784.33 to a maximum of SEK 1,433,045.77 through issue of no more than 7,687,374 shares, each with a quota value of approximately SEK 0.05.

Investment memorandum for the Rights Issue is expected to be published 6 December 2018.

Mangold Fondkommission AB acts as the Emission Institute in the rights issue.

More about the Company and its products: <http://panion-animalhealth.com>

This information is such information as Panion Animal Health AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on November 28, 2018.

Corporate identity number: 559018-4171
The stock's short name: PANION
Share ISIN Code: SE0008963151

For more information contact:
Anja Holm, CEO

Homepage: <http://panion-animalhealth.com>
Mail to: info@panion-animalhealth.com

New postal address:

As part of the process to streamline our internal processes and reduce unnecessary costs, the postal address of Panion has just been moved to:

Panion Animal Health AB
c/o Er Redovisning i Skåne AB
Järnåkravägen 3
SE 222 25 Lund, Sweden

For additional information, contact:

Anja E. H. Holm, CEO | +45-22 94 66 00
anja.holm@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at Spotlight Stock Market.

Panion Animal Health AB
info@panion-animalhealth.com

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 
twitter.com/panionanihealth 
panion-animalhealth.com/newsletter 
panion-animalhealth.com 